Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.
about
Acid suppression and the risk of Clostridium difficile infectionPharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs.Effect of gastrointestinal resection on sunitinib exposure in patients with GIST.Advances in the evaluation and management of esophageal disease of systemic sclerosis.The occurrence and prevention of foodborne disease in vulnerable people.Hypomagnesaemia associated with long-term use of proton pump inhibitorsClopidogrel and proton pump inhibitor (PPI) interaction: separate intake and a non-omeprazole PPI the solution?The diurnal variation in urine acidification differs between normal individuals and uric acid stone formersComparison between Single-Dose Esomeprazole- and Pantoprazole-Based Triple Therapy on the Effectiveness for Helicobacter pylori Eradication in Taiwanese PopulationRisk of community-acquired pneumonia in patients with a diagnosis of pernicious anemia: a population-based retrospective cohort study.Daytime intragastric acid control: post hoc analyses of esomeprazole 20 mg and over-the-counter proton-pump inhibitors.No relevant pharmacokinetic interaction between pantoprazole and mycophenolate in renal transplant patients: a randomized crossover study.Pharmacokinetics of a single 1g dose of azithromycin in rectal tissue in men.Clinical Characteristics of Patients with Gastroesophageal Reflux Disease Refractory to Proton Pump Inhibitors and the Effects of Switching to 20 mg Esomeprazole on Reflux Symptoms and Quality of LifePA32540 for the secondary prevention of cardiovascular disease in patients at risk for aspirin-associated gastric ulcers.Inhibitory effects of intravenous lansoprazole 30 mg and pantoprazole 40 mg twice daily on intragastric acidity in healthy Chinese volunteers: a randomized, open-labeled, two-way crossover studyThe pharmacology of esomeprazole and its role in gastric acid related diseases.Comparative study of esomeprazole and lansoprazole in triple therapy for eradication of Helicobacter pylori in Japan.The pain system in oesophageal disorders: mechanisms, clinical characteristics, and treatmentSystematic review: hypomagnesaemia induced by proton pump inhibition.Individualized therapy for gastroesophageal reflux disease: potential impact of pharmacogenetic testing based on CYP2C19.Rabeprazole for the treatment of acid-related disorders.PA tablets: investigational compounds combining aspirin and omeprazole for cardioprotection.Does gastric acid suppression affect sunitinib efficacy in patients with advanced or metastatic renal cell cancer?Proton pump inhibitors decrease eotaxin-3/CCL26 expression in patients with chronic rhinosinusitis with nasal polyps: Possible role of the nongastric H,K-ATPase.Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment.Rabeprazole exhibits antiproliferative effects on human gastric cancer cell lines.Proton pump inhibitor-induced hypomagnesaemia and hypocalcaemia: case review.Pharmacokinetic and Pharmacodynamic Modeling Analysis of Intravenous Esomeprazole in Healthy Volunteers.The effect of short-term oral treatment with omeprazole or pantoprazole on the function of polymorphonuclear neutrophils.Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.Pharmacokinetics, Pharmacodynamics and Safety of Multiple-Infusion Ilaprazole in Healthy Chinese Subjects.What you need to know when you prescribe a proton pump inhibitor.Effective and safe proton pump inhibitor therapy in acid-related diseases - A position paper addressing benefits and potential harms of acid suppressionEffect of esomeprazole on the oral absorption of dasatinib in a patient with Philadelphia-positive acute lymphoblastic leukemia.Esomeprazole for the treatment of peptic ulcer bleeding.High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates.Pharmacokinetics, pharmacodynamics, and safety of esomeprazole injection/infusion in healthy Chinese volunteers: a five-way crossover study.Combining "Bottom-up" and "Top-down" Approaches to Assess the Impact of Food and Gastric pH on Pictilisib (GDC-0941) Pharmacokinetics.Vonoprazan- vs proton-pump inhibitor-based first-line 7-day triple therapy for clarithromycin-susceptible Helicobacter pylori: A multicenter, prospective, randomized trial.
P2860
Q26823599-D6D87356-71F7-4420-A14E-5B7D29632399Q33698543-DA62F73F-867D-4E1C-A0E8-A18E3E2E7762Q34048307-778B6808-9F17-426D-AC98-105DBE166013Q34666835-FDAA3083-F5D5-46EC-9CCE-C6875C67DA38Q35173590-AA9639BD-398E-478F-8E45-D0EEA081721BQ35923371-37D959CD-CBFF-4065-BC9F-4BC9EB298DC9Q35959258-935EEF83-16D1-465A-9D56-113841B854F4Q35962409-8F7D93BF-F495-4965-9C39-D24FB13E7559Q36100105-402FC9B5-7C65-4926-A2FF-500D9CF82F53Q36101677-387EB8F9-A842-4B80-8C2F-6D9BD6DDAA36Q36212184-706DED6E-4B44-4444-AE6A-5EDDCCA98A60Q36243648-9AFD10B7-D9F2-4DB9-ABBC-734EF52761BBQ36325324-568BECF9-C67A-4651-BF3F-8C910149A84EQ36429167-B0D04030-507F-4D51-A32B-7E3FAD49B76DQ36551017-8EB35291-BDD7-42DB-9037-FD51E97575CCQ36576842-7DE7A28E-3E47-4F84-98FA-6B78BBEFD477Q37552951-620A7919-5451-4331-82F2-F9AD131D52CCQ37708037-BECEBA0A-ACA9-4F4B-938D-BCB1002660B2Q37914003-BB291AD7-41C5-4D6E-98F1-2B6FCDEFEF39Q38023882-DC36CBFE-93D4-4743-8227-648D97C105EEQ38032920-A86821F2-F133-4D89-9711-F6D1FA015364Q38038691-EA11057E-42E5-4BF4-A14A-7FCB0C449927Q38158201-1D647080-F562-4C9B-BFE6-3A47F575F0A2Q38198997-C65A2B72-AE39-4301-BCE6-CE789453CB6EQ38742008-1E3777C5-7424-4412-9C22-774CF3EE0F4CQ38876344-B92B5E24-353A-45B8-9EC4-82D1D978C4BEQ38958255-B6213221-C0E2-47F4-A6DC-A58612D0A133Q39080559-567B6AB0-5F10-4DEB-B192-3AD7B2BEBE11Q39926054-F99298B8-6B12-4877-BABA-0234220B2E14Q40340349-7B8DDCED-A8A6-4EE7-B5C5-EFC1B7F9D81EQ40502852-465945B2-983E-4D44-AE66-3B3438BC6E3CQ40719365-52C776E3-FFD6-4620-B8DA-EEC0B7D78DC5Q41060355-96C069DE-8F61-468E-B75C-7BFF49B368F4Q42371575-BFC68269-A797-454C-8E50-89D35291EEBAQ42770379-DE4549B7-914B-4C43-B3E4-2EBF6E975A35Q42792216-3361C795-CD8C-4C80-9500-EECB7FEE50C0Q44093566-25383556-1067-4B9E-9D84-721B1900EF65Q45125140-4726DA50-A3C5-4E85-A3E4-5F2249291917Q45977183-E8EE2F5D-D288-4605-8C90-E62515C7CBF3Q47672283-BAD7C053-F3C8-43B7-A56A-ECD7E4548D5A
P2860
Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 October 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.
@en
Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.
@nl
type
label
Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.
@en
Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.
@nl
altLabel
Relative potency of proton-pump inhibitors—comparison of effects on intragastric pH
@en
prefLabel
Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.
@en
Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.
@nl
P2093
P1476
Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH.
@en
P2093
Ingolf Meineke
Julia Kirchheiner
Jürgen Brockmöller
Silke Glatt
Ulrich Klotz
P2860
P2888
P356
10.1007/S00228-008-0576-5
P577
2008-10-17T00:00:00Z